AstraZeneca plc (LON:AZN) had its price objective cut by stock analysts at JPMorgan Chase & Co. from GBX 4,900 ($60.79) to GBX 4,600 ($57.06) in a note issued to investors on Monday. The firm presently has a “neutral” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.’s price objective indicates a potential upside of 8.34% from the company’s current price.

Several other brokerages also recently commented on AZN. Jefferies Group set a GBX 5,400 ($66.99) target price on AstraZeneca plc and gave the stock a “neutral” rating in a report on Monday, August 8th. Deutsche Bank AG reaffirmed a “buy” rating and set a GBX 5,800 ($71.95) price objective on shares of AstraZeneca plc in a report on Monday, August 8th. Shore Capital reaffirmed a “hold” rating on shares of AstraZeneca plc in a report on Tuesday, August 9th. Beaufort Securities reaffirmed a “hold” rating on shares of AstraZeneca plc in a report on Wednesday, August 10th. Finally, Goldman Sachs Group Inc. set a GBX 4,000 ($49.62) price objective on AstraZeneca plc and gave the stock a “sell” rating in a report on Wednesday, August 10th. Four analysts have rated the stock with a sell rating, fourteen have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of GBX 4,958.40 ($61.51).

Analyst Recommendations for AstraZeneca plc (LON:AZN)

AstraZeneca plc (LON:AZN) opened at 4234.00 on Monday. AstraZeneca plc has a one year low of GBX 3,680.00 and a one year high of GBX 5,505.00. The stock’s market cap is GBX 53.56 billion. The stock’s 50 day moving average price is GBX 4,592.74 and its 200-day moving average price is GBX 4,592.37.

ILLEGAL ACTIVITY NOTICE: This news story was published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this news story on another website, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2016/11/30/astrazeneca-plc-azn-price-target-cut-to-gbx-4600.html.

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.